Abstract P122 – Table 1. Characteristics of the 14 participants with loss of virological suppression by week 48.
P	Age	Gender/ethnicity	cART directly prior to baseline	RAMs prior to baseline	VL at baseline (copies/mL)	Number of viral blips prior to LVS (copies/mL)	Time to LVS (weeks)	VL at time of LVS (copies/mL)	RAMs at LVS
1	51	M/C	DRV/c/FTC/TAF	NDA	101	Once; 168	36	218	NDA
2	34	F/SSA	FTC/TAF + NVP	NDA	<50	None	48	397	NRTI: 67N, 70R, 184V
3	27	M/SSA	DTG/ABC/3TC	NDA	15 300	None	48	1188	None
4	22	M/SSA	Naïve	None	<50	None	48	588 000	NDA
5	33	F/SSA	DRV/c/FTC/TAF	None	1080	None	48	21 000	NDA
6	46	F/C	DTG/ABC/3TC	NDA	12 600	None	16	418	None
7	45	M/SSA	DRV/c/FTC/TAF	None	<50	None	27	385	NDA
8	55	F/SSA	ABC/3TC + DRV/r	NRTI: 184V INSTI: 66A, 92G	<50	None	32	578	NDA
9	51	M/SSA	Naïve	None	5152	None	17	2154	None
10	55	M/SSA	DTG + FTC/TAF	None	<50	Once; 77	37	457	None
11	31	M/C	Naïve	None	30 233	None	42	11 130	NDA
12	52	M/C	DTG + FTC/TAF	None	<50	None	48	22 700	None
13	34	M/SSA	DRV/c/FTC/TAF	None	<50	None	48	89 200	None
14	42	M/SSA	Naïve	None	932	Once; 182	48	836	NRTI: 184V INSTI: 263K/R

ABC/3TC, abacavir/lamivudine; C, Caucasian; cART, combined antiretroviral therapy; DRV/c, darunavir/cobicistat; DRV/r, darunavir/ritonavir; DTG, dolutegravir; F, female; FTC/TAF, emtricitabine/tenofovir alafenamide; INSTI, integrase strand transfer inhibitor; LVS, loss of virological suppression; M, male; NDA, no data available; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NVP, nevirapine; P, patient; RAMs, resistance‐associated mutations; SSA, black sub‐Saharan African; VL, viral load.